Standard BioTools Q3'26 Earnings Preview: Revenue Estimate 18.80 Million USD
Standard BioTools is scheduled to report Q3'26 results on November 10; revenue is estimated at 18.80 million USD and EPS at (0.02) USD. The release time is unspecified.
Related stories
Yum Brands Says Taco Bell Sales Recovered in Q3
Yum Brands said Taco Bell sales recovered in the third quarter despite the impact of cyclospora. Its CEO said the chain has outgrown quick-service peers since late September.
L impact | EQUITY | Nov 03, 2026, 04:41 PM UTC
Lacroix Group Schedules 2026 Annual Revenue Release
Lacroix Group will release its 2026 annual revenue.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Launches Share Buyback Program of Up to €28.97 Million
Lacroix Group launched a share buyback program of up to €28.97 million.
L impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Announces Annual 2026 Revenue Publication
Lacroix Group says it will publish its annual 2026 revenue. The publication timing is not provided.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Lacroix Group Launches Share Buyback Program for Up to 10% of Capital
Lacroix Group has launched a share buyback program covering up to 10% of its capital.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC
Neurocrine Biosciences Reports Strong Q3 Results, RBC Says
RBC described Neurocrine Biosciences' Q3 results as strong.
M impact | EQUITY | Nov 03, 2026, 04:39 PM UTC